| 000 | 01712 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517090557.0 | ||
| 264 | 0 | _c20170726 | |
| 008 | 201707s 0 0 eng d | ||
| 022 | _a1476-5551 | ||
| 024 | 7 |
_a10.1038/leu.2016.51 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWagle, M | |
| 245 | 0 | 0 |
_aA role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. _h[electronic resource] |
| 260 |
_bLeukemia _c07 2016 |
||
| 300 |
_a1493-501 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aDasatinib _xpharmacology |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aDrug Tolerance |
| 650 | 0 | 4 |
_aForkhead Box Protein O1 _xanalysis |
| 650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImatinib Mesylate _xpharmacology |
| 650 | 0 | 4 |
_aIndazoles _xpharmacology |
| 650 | 0 | 4 | _aK562 Cells |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aSulfonamides _xpharmacology |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aEiring, A M | |
| 700 | 1 | _aWongchenko, M | |
| 700 | 1 | _aLu, S | |
| 700 | 1 | _aGuan, Y | |
| 700 | 1 | _aWang, Y | |
| 700 | 1 | _aLackner, M | |
| 700 | 1 | _aAmler, L | |
| 700 | 1 | _aHampton, G | |
| 700 | 1 | _aDeininger, M W | |
| 700 | 1 | _aO'Hare, T | |
| 700 | 1 | _aYan, Y | |
| 773 | 0 |
_tLeukemia _gvol. 30 _gno. 7 _gp. 1493-501 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/leu.2016.51 _zAvailable from publisher's website |
| 999 |
_c25892946 _d25892946 |
||